FDA FAERS Analysis

ADHD
Medication
Safety Data.

Independent analysis of FDA adverse event reports for ADHD stimulant medications. Data-driven safety signals, not medical advice.

Explore Documentation Safety Data

FDA FAERS public database — primary source
Vyvanse, Adderall, and 23 comparator drugs
Abuse, dependence, and misuse signal analysis

Key Findings

5,803Adverse eventsVyvanse FAERS reports (primary)

1.8×Higher abuse riskvs. comparator stimulants

23 drugsComparators reviewedacross stimulant class

FAERSPrimary data sourceFDA public adverse event database

Source: FDA FAERS public database. This analysis is independent and not affiliated with the FDA. For informational purposes only.

Documentation

What's Covered

Safety Data

Quantitative FAERS adverse event counts, abuse/dependence signals, and comparative analysis across ADHD stimulant medications.

Clinical Studies

Human abuse potential study findings, controlled trials, and post-market surveillance data for Vyvanse and related drugs.

Prescribing Context

Real-world prescribing trends, off-label use patterns, and regulatory labeling requirements for ADHD stimulants.

Vyvanse Full Review

Comprehensive FDA-style safety review covering efficacy, abuse potential, post-market experience, ethics, and recommendations.

Important Notice